Cover Image
市場調查報告書

Hetero Drugs Limited的產品平台分析

Hetero Drugs Limited - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 321959
出版日期 內容資訊 英文 23 Pages
訂單完成後即時交付
價格
Back to Top
Hetero Drugs Limited的產品平台分析 Hetero Drugs Limited - Product Pipeline Review - 2015
出版日期: 2015年12月30日 內容資訊: 英文 23 Pages
簡介

Hetero Drugs Limited是總公司設立於印度,以研究為基礎的製藥企業。正在從事API、化學中間體、最後製劑等的研究開發、製造與銷售。該公司專門製造開發生技仿製藥,提供全球生物科技企業·製藥企業客製化研究及製造服務。

本報告提供Hetero Drugs Limited的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

Hetero Drugs Limited的基本資料

  • Hetero Drugs Limited概要
  • 主要資訊
  • 企業資料

Hetero Drugs Limited:R&D概要

  • 主要的治療範圍

Hetero Drugs Limited:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式

Hetero Drugs Limited:開發中產品概況

  • 最後階段的開發中產品
    • 第三階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 藥物研發中的產品/聯合治療模式

Hetero Drugs Limited:藥物簡介

  • rituximab biosimilar
  • Small Molecules for Diabetes
  • Small Molecules for Hepatitis C
  • Small Molecules for HIV

Hetero Drugs Limited:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Hetero Drugs Limited:暫停中的計劃

Hetero Drugs Limited:總公司和子公司的所在地

  • 總公司
  • 分公司及子公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07934CDB

Summary

Global Markets Direct's, 'Hetero Drugs Limited - Product Pipeline Review - 2015', provides an overview of the Hetero Drugs Limited's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Hetero Drugs Limited's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Hetero Drugs Limited including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Hetero Drugs Limited's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Hetero Drugs Limited's pipeline products

Reasons to buy

  • Evaluate Hetero Drugs Limited's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Hetero Drugs Limited in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Hetero Drugs Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Hetero Drugs Limited and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Hetero Drugs Limited
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Hetero Drugs Limited and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Hetero Drugs Limited Snapshot
    • Hetero Drugs Limited Overview
    • Key Information
    • Key Facts
  • Hetero Drugs Limited - Research and Development Overview
    • Key Therapeutic Areas
  • Hetero Drugs Limited - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Hetero Drugs Limited - Pipeline Products Glance
    • Hetero Drugs Limited - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Hetero Drugs Limited - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Hetero Drugs Limited - Drug Profiles
    • adalimumab biosimilar
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • bevacizumab biosimilar
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • trastuzumab biosimilar
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Hetero Drugs Limited - Pipeline Analysis
  • Hetero Drugs Limited - Pipeline Products by Target
  • Hetero Drugs Limited - Pipeline Products by Route of Administration
  • Hetero Drugs Limited - Pipeline Products by Molecule Type
  • Hetero Drugs Limited - Pipeline Products by Mechanism of Action
  • Hetero Drugs Limited - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Hetero Drugs Limited, Key Information
  • Hetero Drugs Limited, Key Facts
  • Hetero Drugs Limited - Pipeline by Indication, 2015
  • Hetero Drugs Limited - Pipeline by Stage of Development, 2015
  • Hetero Drugs Limited - Monotherapy Products in Pipeline, 2015
  • Hetero Drugs Limited - Partnered Products in Pipeline, 2015
  • Hetero Drugs Limited - Partnered Products/ Combination Treatment Modalities, 2015
  • Hetero Drugs Limited - Phase III, 2015
  • Hetero Drugs Limited - Preclinical, 2015
  • Hetero Drugs Limited - Pipeline by Target, 2015
  • Hetero Drugs Limited - Pipeline by Route of Administration, 2015
  • Hetero Drugs Limited - Pipeline by Molecule Type, 2015
  • Hetero Drugs Limited - Pipeline Products by Mechanism of Action, 2015
  • Hetero Drugs Limited, Other Locations
  • Hetero Drugs Limited, Subsidiaries

List of Figures

  • Hetero Drugs Limited - Pipeline by Top 10 Indication, 2015
  • Hetero Drugs Limited - Pipeline by Stage of Development, 2015
  • Hetero Drugs Limited - Monotherapy Products in Pipeline, 2015
  • Hetero Drugs Limited - Pipeline by Top 10 Target, 2015
  • Hetero Drugs Limited - Pipeline by Top 10 Route of Administration, 2015
  • Hetero Drugs Limited - Pipeline by Top 10 Molecule Type, 2015
  • Hetero Drugs Limited - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top